Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neuroblastoma - Overview
Neuroblastoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neuroblastoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neuroblastoma - Companies Involved in Therapeutics Development
Neuroblastoma - Drug Profiles
Neuroblastoma - Dormant Projects
Neuroblastoma - Discontinued Products
Neuroblastoma - Product Development Milestones
Featured News & Press Releases
Oct 28, 2022: Y-mAbs announces scheduling of FDA advisory committee meeting for Omburtamab
Oct 03, 2022: Y-mAbs announces pivotal data for Omburtamab
Sep 26, 2022: Y-mAbs announces regulatory filing for DANYELZA (xitamab-gqgk) in Brazil
Aug 30, 2022: Y-mAbs and Takeda announces marketing authorization in Israel for DANYELZA (xitamab-gqgk) for neuroblastoma
Jul 26, 2022: The global pharmaceutical industry is accelerating; Aptorum Group has received orphan drug desigtion from US FDA for its SACT-1
Jun 28, 2022: SciClone Pharmaceuticals : NMPA approval of IND of DANYELZA (xitamab) and GM-CSF in combition with Irinotecan and Temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse
Jun 03, 2022: Y-mAbs announces xitamab chemoimmunotherapy investigatiol trial for high-risk neuroblastoma meets primary endpoint
May 31, 2022: Y-mAbs announces FDA Acceptance of Biologics License Application for OMBLASTYS (omburtamab) for the treatment of Neuroblastoma for Priority Review
May 02, 2022: Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to present phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma at the ASGCT 25th Annual Meeting
May 02, 2022: Aptorum Group updates on data from the completed phase 1 clinical trial of SACT-1, targeting neuroblastoma
Apr 23, 2022: Nektar and collaborators present preclinical data on NKTR-255, a novel IL-15 receptor agonist, in combition with CAR cell therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Apr 20, 2022: Nmpa acceptance of IND of Danyelza (xitamab) and GM-CSF in combition with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse
Mar 21, 2022: Ascentage Pharma’s MDM2-p53 inhibitor alrizomadlin (APG-115) granted Rare Pediatric Disease Desigtion by the US FDA for the treatment of neuroblastoma
Feb 11, 2022: Y-mAbs announces completion of Pre-BLA meeting with FDA for Omburtamab
Jan 20, 2022: Aptorum Group receives FDA Orphan Drug Desigtion for its SACT-1 repurposed drug for the treatment of neuroblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Neuroblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Neuroblastoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Neuroblastoma - Dormant Projects, 2022
Neuroblastoma - Discontinued Products, 2022